Lin Cheng-Wen, Gonzalez Pedro, Yuan Fan
Department of Biomedical Engineering, Duke University, Durham, NC, USA.
Mol Vis. 2011;17:2507-15. Epub 2011 Sep 27.
Ethacrynic acid (ECA) is a potential trabecular meshwork (TM) drug that has shown promising results in preclinical studies for treatment of primary open-angle glaucoma. However, topical application of ECA is currently limited by adverse effects in corneal tissues. To this end, we developed a new theoretical model to evaluate time-dependent toxicity induced by ECA in corneal epithelial cells.
The model consisted of a cellular pharmacokinetic (PK) module to determine intracellular concentration of ECA, and a pharmacodynamic (PD) module to determine the cytotoxicity of ECA. It was assumed that ECA-induced cytotoxicity depended on drug exposure time and peak concentration of bound ECA in cells. In addition to the model development, we experimentally determined the intracellular concentration of ECA as a function of drug dose and treatment time.
The intracellular concentration increased linearly (i.e., no saturation) with increasing the dose of ECA. It also increased initially with time and then reached a steady-state at ~40 min. The percent of cells survived after treatment decreased with increasing the dose of drug or the time of treatment. The experimental data were fit by the new PK and PD models to obtain values of model constants. One of the unique applications of these models was to predict cell survival relative to control when extracellular concentration of ECA varied with time. The prediction showed that the toxicity of ECA might be significantly overestimated by using the traditional LC(50) determined in vitro.
The new PK and PD models developed in this study were capable to fit experimental data and predict time-dependent toxicity of ECA in corneal epithelial cells. The models may be useful for optimizing the dose and schedule in topical application of ECA for glaucoma treatment.
依他尼酸(ECA)是一种潜在的小梁网(TM)药物,在原发性开角型青光眼治疗的临床前研究中已显示出有前景的结果。然而,ECA的局部应用目前受到角膜组织不良反应的限制。为此,我们开发了一种新的理论模型来评估ECA在角膜上皮细胞中诱导的时间依赖性毒性。
该模型由一个细胞药代动力学(PK)模块来确定ECA的细胞内浓度,以及一个药效动力学(PD)模块来确定ECA的细胞毒性。假设ECA诱导的细胞毒性取决于药物暴露时间和细胞内结合ECA的峰值浓度。除了模型开发外,我们还通过实验确定了ECA的细胞内浓度作为药物剂量和治疗时间的函数。
细胞内浓度随着ECA剂量的增加呈线性增加(即无饱和现象)。它也随时间最初增加,然后在约40分钟时达到稳态。处理后存活细胞的百分比随着药物剂量或处理时间的增加而降低。实验数据通过新的PK和PD模型进行拟合以获得模型常数的值。这些模型的独特应用之一是当ECA的细胞外浓度随时间变化时预测相对于对照的细胞存活率。预测表明,使用体外测定的传统半数致死浓度(LC50)可能会显著高估ECA的毒性。
本研究中开发的新PK和PD模型能够拟合实验数据并预测ECA在角膜上皮细胞中的时间依赖性毒性。这些模型可能有助于优化ECA局部应用于青光眼治疗的剂量和给药方案。